SCHEMBL312151

SCHEMBL312151

O=c1cc(-c2ccc(O)cc2)oc2ccc(O)nc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.59
MAPT P10636 7/20 0.59
HPGD P15428 6/20 0.59
NPC1 O15118 6/20 0.59
RAB9A P51151 5/20 0.59
TP53 P04637 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
IP6K2 Q9UHH9 4/20 0.59
LMNA P02545 2/20 0.59
THRB P10828 2/20 0.59
ALOX15 P16050 2/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
KDM4E B2RXH2 6/20 0.55
ALDH1A1 P00352 5/20 0.55
MAPK1 P28482 4/20 0.55
HSD17B10 Q99714 4/20 0.55
MPO P05164 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314322 0.79 CYP3A4 (0.52) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL311223 0.78 KDM4E (0.60) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL312658 0.77 CYP3A4 (0.46) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL311672 0.77 CYP3A4 (0.46) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL312405 0.76 CYP3A4 (0.59) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL312113 0.76 CYP3A4 (0.59) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL31741263 0.74 MAPT (1.00) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL311405 0.74 MAPT (1.00) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL312565 0.74 CYP3A4 (0.52) CYP3A4MAPTHPGDNPC1RAB9A
SCHEMBL29636735 0.72 LCK (0.78) CYP3A4MAPTHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 CYP3A4 1730/4885MAPT 2914/4885HPGD 138/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 CYP3A4 1730/4885MAPT 2914/4885HPGD 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.